UCB S.A. - SWOT, Strategy and Corporate Finance Report

UCB S.A. - SWOT, Strategy and Corporate Finance Report - new company profile report published
2013-01-23 18:34:55 - UCB S.A. - SWOT, Strategy and Corporate Finance Report - a new company profile report on

UCB S.A. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company´s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.


- Detailed information on UCB S.A. required for business and competitor intelligence needs
- A study of the major



internal and external factors affecting UCB S.A. in the form of a SWOT analysis
- An in-depth view of the business model of UCB S.A. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for UCB S.A.
- Intelligence on UCB S.A.nv´s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about UCB S.A., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends


UCB is a global biopharmaceutical company. The company focuses on severe diseases in the fields of central nervous system (CNS) disorders and autoimmune and inflammatory diseases (AIID). It has operations in about 40 countries in Europe, North America, Asia, Africa, Oceania and South America. It is headquartered in Brussels, Belgium and employed 8,898 people as of December 31, 2010. The company recorded revenues of E3,218 million ($4,269.3 million*) during the financial year (FY) ended December 2010, an increase of 3.3% over 2009. The operating profit of the company was E204 million ($270.6 million*) during FY2010, a decrease of 75.6% over 2009. The net profit was E103 million ($136.7 million*) in FY2010, a decrease of 79.9% over 2009. * Calculated using a constant conversion rate of E1 = $1.3267 for year ended December 31, 2010.
Reasons to Purchase:

- Gain understanding of UCB S.A. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess UCB S.A. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers´ businesses better
- Stay up to date on UCB S.A.´s business structure, strategy and prospects

Click for report details: ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Company Profile Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Telefon: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.